Funda Meric‐Bernstam
0000-0001-6816-6072
Publication & Citation Trends
Publications
0 total
Global patterns of mutational profiles in biliary tract cancer
Cited by 0
Semantic Scholar
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors OA
Cited by 21
Semantic Scholar
Abstract 5141: Autoantibody profiling for predictive biomarkers for immune-related adverse events and clinical benefit in rare tumors treated with anti-PD-1 therapy
Cited by 0
Semantic Scholar
Abstract 4536: MTAP loss alters the epigenetic landscape and demonstrates superior therapeutic sensitivity to concomitant PRMT5 and PARP inhibition in cholangiocarcinoma
Cited by 2
Semantic Scholar
Abstract 939: Comprehensive genomic and transcriptomic analysis to guide therapy for patients with metastatic solid tumors
Cited by 0
Semantic Scholar
Abstract B035: Cyclin E1 positive staining is frequent and independent of prior platinum treatment in high grade serous ovarian cancer
Cited by 0
Semantic Scholar
Abstract 1209: Tumor informed circulating tumor DNA monitoring for early treatment response and survival outcomes on trastuzumab + pertuzumab
Cited by 0
Semantic Scholar
Abstract 3317: KRASmulti inhibitor BI 3706674 shows efficacy in KRAS-driven preclinical models of cancer that supports clinical testing in patients with tumors harbouring KRASG12V mutations and KRAS wild-type amplifications
Cited by 10
Semantic Scholar
Research Topics
Cancer Genomics and Diagnostics
(666)
HER2/EGFR in Cancer Research
(343)
Lung Cancer Treatments and Mutations
(327)
Breast Cancer Treatment Studies
(280)
Advanced Breast Cancer Therapies
(275)
Affiliations
University of North Carolina at Chapel Hill
Ben-Gurion University of the Negev
Novartis (Switzerland)
Houston Methodist
Beth Israel Deaconess Medical Center